Search - tctmd.com

Displaying 141 - 160 of 193

Sort: Relevancy | Date

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

News Daily News

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

May 04, 2018

Doctors, Risk Tools Often at Odds When Assessing Risks in Patients With A-fib Undergoing PCI

News Conference News SCAI 2018

Doctors, Risk Tools Often at Odds When Assessing Risks in Patients With A-fib Undergoing PCI

April 27, 2018

Reversal Agent for Factor Xa Inhibitors Continues to Look Good: ANNEXA-4

News Conference News ACC 2018

Reversal Agent for Factor Xa Inhibitors Continues to Look Good: ANNEXA-4

March 13, 2018

Apixaban Has Edge Over Other NOACs in Large, Real-World Analysis

News Conference News ACC 2018

Apixaban Has Edge Over Other NOACs in Large, Real-World Analysis

March 12, 2018

Ticagrelor: Better Platelet Blockade Post-TAVR?

News Conference News CRT 2018

Ticagrelor: Better Platelet Blockade Post-TAVR?

Michael O'Riordan

March 07, 2018

One in Five CABG Patients Develop New-Onset Atrial Fibrillation: EXCEL

News Daily News

One in Five CABG Patients Develop New-Onset Atrial Fibrillation: EXCEL

Michael O'Riordan

February 12, 2018

Experts Debate: Is It ‘Nuts’ to Restart Anticoagulation After Lobar ICH?

News Conference News ISC 2018

Experts Debate: Is It ‘Nuts’ to Restart Anticoagulation After Lobar ICH?

January 30, 2018

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

December 26, 2017

ACC Provides Guidance on How to Manage Bleeding in Patients Taking Oral Anticoagulants

News Daily News

ACC Provides Guidance on How to Manage Bleeding in Patients Taking Oral Anticoagulants

December 04, 2017

RE-DUAL PCI Findings Consistent Across Key Subgroups

News Conference News AHA 2017

RE-DUAL PCI Findings Consistent Across Key Subgroups

November 16, 2017

Continuing NOACs During Device Surgery Does Not Reduce Pocket Hematoma

News Conference News AHA 2017

Continuing NOACs During Device Surgery Does Not Reduce Pocket Hematoma

November 15, 2017

Longer-term Outcomes of Watchman Reassure as Debate Continues Over How It Should Be Used

News Conference News TCT 2017

Longer-term Outcomes of Watchman Reassure as Debate Continues Over How It Should Be Used

November 02, 2017

IMPACT-AF: Education, Feedback Boost Oral Anticoagulation Use for A-fib

News Conference News ESC 2017

IMPACT-AF: Education, Feedback Boost Oral Anticoagulation Use for A-fib

August 30, 2017

Dabigatran Reversal Agent Yields No Surprises in Final RE-VERSE AD Study Results

News Daily News

Dabigatran Reversal Agent Yields No Surprises in Final RE-VERSE AD Study Results

July 14, 2017

Early Cardiology Care Tied to Better Outcomes for New A-fib Patients

News Daily News

Early Cardiology Care Tied to Better Outcomes for New A-fib Patients

June 26, 2017

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

News Daily News

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

May 23, 2017

Prevalence, Management, and Long-term (6-Year) Outcomes of A-fib Among Patients Receiving DES

Presentation

Prevalence, Management, and Long-term (6-Year) Outcomes of A-fib Among Patients Receiving DES

May 23, 2017

‘Reassuring’ Results for Watchman LAA Closure Device Seen in EWOLUTION Registry

News Daily News

‘Reassuring’ Results for Watchman LAA Closure Device Seen in EWOLUTION Registry

May 17, 2017

Do NOACs Carry a Higher Risk of Acute MI? New Study Reopens Old Questions

News Daily News

Do NOACs Carry a Higher Risk of Acute MI? New Study Reopens Old Questions

March 28, 2017

NOACs Seem to Perform Just Fine in Patients With A-fib and Most Types of Valvular Disease

News Daily News

NOACs Seem to Perform Just Fine in Patients With A-fib and Most Types of Valvular Disease

March 14, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.